Opendata, web and dolomites

PMLingAML SIGNED

Using PML nuclear body biology to identify potential AML treatment targets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMLingAML project word cloud

Explore the words cloud of the PMLingAML project. It provides you a very rough idea of what is the project "PMLingAML" about.

carry    majority    promyelocytes    inter    isolated    functions    scrutinised    leukemic    assuredly    nbs    alpha    dactinomycin    biology    model    ber    nb    acute    body    underlying    lsk    base    mutation    formerly    flt3itd    share    vast    relationship    poor    progenitor    bone    leukemia    npm1    mechanisms    therapy    strategies    clinical    models    myeloid    disrupted    rar    successful    previously    pml    spectrometry    pmlc62a    mimics    nuclear    leukemogenesis    excision    roles    lethal    mass    status    sumoylome    resolution    cured    identification    hematopoietic    initiation    outcome    trial    repair    murine    drug    treatment    dna    promyelocytic    oncoprotein    localisation    shown    cells    apl    npm1c    dynamics    mutated    patient    decipher    imaging    healthy    patients    disruption    respective    function    pmlingaml    therapeutic    incl    combination    samples    mouse    subset    stem    cellular    elucidating    understanding    aml    pathogenesis    marrows    analysing    damage    knock    c65a   

Project "PMLingAML" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 184˙707 €
 EC max contribution 184˙707 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 184˙707.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Understanding the initiation and development of acute myeloid leukemia (AML) represents an important challenge which may lead to the identification of new therapeutic strategies. Acute promyelocytic leukemia (APL) was formerly the most lethal subset of AML; however, today the vast majority of APL patients can be cured by combination therapy. Therefore, fully understanding the mechanisms underlying successful treatment, by analysing the biology of APL pathogenesis will assuredly improve the management of AML subsets associated with a poor outcome, such as NPM1-mutated AML. Using a novel knock-in mouse model, PmlC62A/C65A, which mimics Pml nuclear body (NB) disruption induced by the main oncoprotein PML-RARα in APL, we have previously shown that Pml NBs are essential in APL pathogenesis and treatment response. Our project “PMLingAML” aims to carry on elucidating the impact of Pml NB disruption in APL, and then to apply this knowledge in other AML subsets. To this end, a mass spectrometry analysis will be conducted on both hematopoietic stem and progenitor (LSK) cells and promyelocytes isolated from healthy and leukemic murine bone marrows, to decipher the consequences of Pml NB disruption on the SUMOylome. Next, since PML NBs and NPM1 share common cellular functions and characteristics, we will analyse the inter-relationship between them; their localisation and dynamics will be assessed according to their respective status (disruption, mutation, knock-out), for example by high resolution imaging, both in various healthy and leukemic mouse models (incl NPM1c and NPM1c/FLT3ITD), and in patient samples. Their respective roles in response to a drug under clinical trial, Dactinomycin, will also be scrutinised. Finally, as DNA damage repair is an important function disrupted during leukemogenesis, the roles of Pml NBs and Npm1 will be assessed together with their inter-relationship, with particular focus on the base excision repair (BER) pathway.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMLINGAML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMLINGAML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More  

AsymmFlow (2020)

Go with the continuous flow: Asymmetric Synthesis of Bioactive Alkaloids by Multistep Continuous-Flow Processes

Read More